Want to see LUCD full AI Analyst Report?
Lucid Diagnostics (LUCD) Stock Statistics & Valuation Metrics
Total Valuation
Lucid Diagnostics has a market cap or net worth of $82.27M. The enterprise value is $187.45M.
- Market Cap
- $82.27M
- Enterprise Value
- $187.45M
Share Statistics
Lucid Diagnostics has 203,243,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 203,243,970
- Owned by Insiders
- 5.36%
- Owned by Institutions
- 15.21%
Financial Efficiency
Lucid Diagnostics’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -135.05%.
- Return on Equity (ROE)
- -5.30
- Return on Assets (ROA)
- -1.43
- Return on Invested Capital (ROIC)
- -135.05%
- Return on Capital Employed (ROCE)
- -4.18
- Revenue Per Employee
- 57.39K
- Profits Per Employee
- -707.44K
- Employee Count
- 82
- Asset Turnover
- 0.12
- Inventory Turnover
- 21.37
Valuation Ratios
The current PE Ratio of Lucid Diagnostics is -0.87. Lucid Diagnostics’s PEG ratio is -0.01.
- PE Ratio
- -0.87
- PS Ratio
- 14.20
- PB Ratio
- 6.78
- Price to FCF
- -1.64
- Price to Operating Cash Flow
- -1.58
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Lucid Diagnostics had revenue of 4.71M and earned -58.01M in profits. Earnings per share was -0.69.
- Revenue
- 4.71M
- Gross Profit
- -2.84M
- Operating Income
- -49.64M
- Pretax Income
- -58.01M
- Net Income
- -58.01M
- EBITDA
- -57.12M
- Earnings Per Share (EPS)
- -0.69
Cash Flow
In the last 12 months, operating cash flow was -46.87M and capital expenditures -315,000, giving a free cash flow of -47.18M billion.
- Operating Cash Flow
- -46.87M
- Free Cash Flow
- -47.18M
- Free Cash Flow per Share
- -0.26
Dividends & Yields
Lucid Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -61.04%
- Earnings Yield
- -70.50%
Stock Price Statistics
- Beta
- 0.61
- 52-Week Price Change
- -66.33%
- 50-Day Moving Average
- 0.71
- 200-Day Moving Average
- 1.02
- Relative Strength Index (RSI)
- 35.59
- Average Volume (3m)
- 4.52M
Important Dates
Lucid Diagnostics upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Lucid Diagnostics as a current ratio of 1.31, with Debt / Equity ratio of 236.10%
- Current Ratio
- 1.31
- Quick Ratio
- 1.30
- Debt to Market Cap
- 0.22
- Net Debt to EBITDA
- 0.16
- Interest Coverage Ratio
- -2256.36
Taxes
In the past 12 months, Lucid Diagnostics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Lucid Diagnostics EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.46.
- EV to Sales
- 12.64
- EV to EBITDA
- -1.34
- EV to Free Cash Flow
- -1.46
- EV to Operating Cash Flow
- -1.47
Balance Sheet
Lucid Diagnostics has $33.40M in cash and marketable securities with $24.91M in debt, giving a net cash position of $8.49M billion.
- Cash & Marketable Securities
- $33.40M
- Total Debt
- $24.91M
- Net Cash
- $8.49M
- Net Cash Per Share
- $0.04
- Tangible Book Value Per Share
- $0.06
Margins
Gross margin is -25.79%, with operating margin of -930.85%, and net profit margin of -959.76%.
- Gross Margin
- -25.79%
- Operating Margin
- -930.85%
- Pretax Margin
- -959.76%
- Net Profit Margin
- -959.76%
- EBITDA Margin
- -943.36%
- EBIT Margin
- -959.43%
Analyst Forecast
The average price target for Lucid Diagnostics is $4.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $4.00
- Price Target Upside
- 890.10% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 24.89%
- EPS Growth Forecast
- 55.16%
Scores
- Smart Score
- 3
- AI Score
- 45
